Neratinib in Extended Adjuvant Treatment for HER2+ Early Breast Cancer With pCR But High-Risk Features: A Hebei Multi-Center Real-World Study

NCT07019272 · clinicaltrials.gov ↗

NOT_YET_RECRUITING

Status

170

Enrollment

OTHER

Sponsor class

Conditions

HER2-positive Breast Cancer

Interventions

DRUG: Neratinib (HKI-272)

Sponsor

Hebei Medical University Fourth Hospital